Guselkumab Response Durable in Psoriatic Arthritis

(MedPage Today) -- The efficacy of the monoclonal antibody guselkumab (Tremfya) persisted through 2 years of follow-up among patients with active psoriatic arthritis (PsA), a researcher reported at the virtual American College of Rheumatology ...